Humira® – Adalimumab Injection

Humira® – Adalimumab Injection | U.S.-Manufactured Global Supply TNF-α Inhibitor

Product Overview

Humira® (adalimumab) is a fully human IgG1 monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α) — a key mediator in chronic inflammatory and autoimmune disorders. Developed and manufactured by AbbVie Inc. (USA), Humira® is one of the most widely prescribed biologic therapies globally, with approvals in over 100 countries.

The version offered here is manufactured in the United States by the originator company and distributed through AbbVie’s global pharmaceutical supply chain. While packaging and labeling may vary by regulatory requirements in the destination market, the formulation, device system, and quality standards are identical to the U.S.-marketed product.

---

Key Features & Advantages

• ✅ U.S.-Manufactured Original Product
  Produced by AbbVie Inc. under FDA and global GMP standards.

• ✅ Global Standard Formulation
  Only outer carton and leaflet are localized; drug content and autoinjector/syringe system remain identical.

• ✅ One of the Most Prescribed Biologics Worldwide
  Proven efficacy across a broad range of autoimmune and inflammatory diseases.

• ✅ Approved in Over 100 Countries
  Supported by 20+ years of safety and efficacy data in real-world and clinical settings.

• ✅ Reliable Global Supply
  Available to licensed importers, hospitals, and institutional buyers.

---

Product Specifications

• Product Name: Humira® (adalimumab injection)

• Active Ingredient: Adalimumab (recombinant human IgG1 monoclonal antibody)

• Strength / Form: 40 mg/0.8 mL prefilled syringe or pen (standard); other strengths available depending on region

• Administration: Subcutaneous injection

• Manufacturer: AbbVie Inc. (USA)

• Packaging: Destination-market specific labeling (e.g., Chinese, English, Arabic); identical formulation globally

• Storage: 2°C–8°C; do not freeze

• Shelf Life: 24 months from manufacture

• Supply Type: Originator biologic; not a biosimilar

---

Mechanism of Action

Humira® binds specifically to TNF-α, neutralizing its biological activity by preventing interaction with its surface receptors (p55 and p75) on inflammatory cells. By inhibiting TNF-α, Humira® reduces systemic inflammation and halts the autoimmune-driven damage characteristic of multiple chronic conditions.

Clinical outcomes include:

• Reduced joint swelling and structural damage in RA and PsA

• Lowered disease activity in IBD and axial spondyloarthritis

• Significant clearance of skin lesions in psoriasis

• Long-term disease control across indications

More: NIH: Adalimumab Mechanism Overview

---

Indications (may vary by region)

• Rheumatoid Arthritis (RA)

• Psoriatic Arthritis (PsA)

• Ankylosing Spondylitis (AS)

• Crohn’s Disease (CD)

• Ulcerative Colitis (UC)

• Plaque Psoriasis (PP)

• Hidradenitis Suppurativa (HS)

• Juvenile Idiopathic Arthritis (JIA)

• Uveitis (non-infectious)

---

Compliance Statement

This product is manufactured in the United States by AbbVie Inc. and is distributed internationally through the originator’s official global supply network. The formulation, strength, and delivery system are identical to the U.S.-approved product. Only packaging language and regulatory markings may differ by region. This product is not a biosimilar. Licensed importers and healthcare institutions are responsible for compliance with applicable local regulations.

---

Tags / Keywords

Humira, Adalimumab Injection, Original TNF-Alpha Inhibitor, AbbVie Biologic, U.S.-Manufactured Humira, Global Supply Biologics, Rheumatoid Arthritis Monoclonal Antibody, Crohn’s Disease Biologic, Psoriasis Therapy, Not a Biosimilar